Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zenas BioPharma (ZBIO) Depreciation & Amortization (CF) (2023 - 2025)

Zenas BioPharma has reported Depreciation & Amortization (CF) over the past 3 years, most recently at $10000.0 for Q4 2025.

  • Quarterly results put Depreciation & Amortization (CF) at $10000.0 for Q4 2025, down 69.7% from a year ago — trailing twelve months through Dec 2025 was $56000.0 (down 59.12% YoY), and the annual figure for FY2025 was $56000.0, down 59.12%.
  • Depreciation & Amortization (CF) for Q4 2025 was $10000.0 at Zenas BioPharma, down from $11000.0 in the prior quarter.
  • Over the last five years, Depreciation & Amortization (CF) for ZBIO hit a ceiling of $36000.0 in Q3 2024 and a floor of $10000.0 in Q4 2025.
  • Median Depreciation & Amortization (CF) over the past 3 years was $30000.0 (2023), compared with a mean of $24777.8.
  • Biggest five-year swings in Depreciation & Amortization (CF): increased 10.0% in 2024 and later plummeted 69.7% in 2025.
  • Zenas BioPharma's Depreciation & Amortization (CF) stood at $30000.0 in 2023, then increased by 10.0% to $33000.0 in 2024, then plummeted by 69.7% to $10000.0 in 2025.
  • The last three reported values for Depreciation & Amortization (CF) were $10000.0 (Q4 2025), $11000.0 (Q3 2025), and $12000.0 (Q2 2025) per Business Quant data.